Oslo, 29 April 2022 – Navamedic ASA (OSE: NAVA) publishes its annual report for 2021. The report is attached and available on navamedic.com/investors. Additionally, the company's Annual Report in European Single Electronic Format (ESEF) is attached, please refer to the zip-file.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: firstname.lastname@example.org
Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: email@example.com
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.